← SynDRA
VX-702
SynDRA canonical compound SYN0021677 — structure-anchored drug synonym record
| Clinical phase | Phase 2 |
|---|
| Primary target(s) | MAPK14 |
|---|
| Mechanism of action | P38 MAPK inhibitor |
|---|
All known targets
- MAPK14
- MAPK11
- IL1B
- IL6
- MAPK12
- TNF
Mechanisms of action (all sources)
- MAPK14 INHIBITOR
- MAP kinase p38 alpha inhibitor
- MAPK11 INHIBITOR
- MAPK14 MODULATOR
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- NQO2
- PIM1
- PI4KB
- PHKG2
- PGRMC1
- PFKP
- PEBP1
- PDXK
- PDGFRB
- PASK
- PAK6
- PAK4
- PAICS
- OPA1
- OLA1
- NUAK2
- PIP4K2A
- PIP4K2C
- PKMYT1
- PRKACG
- PRKCD
- PRKCB
- PRKCA
- PRKAR2A
- PRKAG2
- PRKAG1
- PRKACB
- PKN1
- PRKACA
- PRKAA1
- PLK4
- PLK1
- PKN3
- PKN2
- NTRK1
- NME2P1
- PRKCQ
- NME2
- MARK4
Cross-references
Synonyms
- ST51054128
- I14-1965
- EC-000.2363
- 6-[carbamoyl-(2,6-difluorophenyl)amino]-2-(2,4-difluorophenyl)pyridine-3-carboxamide
- VX702
- UNII-527E7SK68P
- KVK 702
- VX702 cpd
- VX805 cpd
- VX954 cpd
- RefChem:194709
- KVK702
- VX-850
- VX-954
- MFCD11616590
- C19H12F4N4O2
- Kinome_3176
- VX-702, Free Base
- MLS006011165
- orb322883
- SCHEMBL185712
- GTPL6059
- orb1305373
- SCHEMBL29352789
- SCHEMBL29367579
- SCHEMBL29394821
- CHEBI:94489
- EX-A013
- FYSRKRZDBHOFAY-UHFFFAOYSA-N
- GLXC-05171
- HMS3244H04
- HMS3244H08
- HMS3244H12
- HMS3656J20
- HMS3674G05
- EUA54346
- BDBM50314071
- HB1308
Look up VX-702 in the interactive SynDRA portal →